Double immune attack: new combo therapy targets Hard-to-Treat head and neck cancers
NCT ID NCT01468896
First seen Mar 28, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This study tested a combination of two drugs—cetuximab and interleukin-12—in 23 people with head and neck cancer that had spread, returned, or could not be surgically removed. The goal was to find the safest dose of interleukin-12 when given with cetuximab and to see if the pair could shrink tumors. The approach aims to boost the body's immune system to better fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.